BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 535127)

  • 1. Phase-II trial of tamoxifen in advanced breat cancer.
    Wiggans RG; Woolley PV; Smythe T; Hoth D; Macdonald JS; Green L; Schein PS
    Cancer Chemother Pharmacol; 1979; 3(1):45-8. PubMed ID: 535127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer.
    Lerner HJ; Band PR; Israel L; Leung BS
    Cancer Treat Rep; 1976 Oct; 60(10):1431-5. PubMed ID: 798626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters.
    Morgan LR; Schein PS; Woolley PV; Hoth D; Macdonald J; Lippman M; Posey LE; Beazley RW
    Cancer Treat Rep; 1976 Oct; 60(10):1437-43. PubMed ID: 191185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate and 5-fluorouracil following tamoxifen and premarin in advanced breast cancer.
    Allegra JC
    Semin Oncol; 1983 Jun; 10(2 Suppl 2):23-8. PubMed ID: 6306835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of tamoxifen in advanced male breast cancer.
    Patterson JS; Battersby LA; Bach BK
    Cancer Treat Rep; 1980; 64(6-7):801-4. PubMed ID: 7427964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen (antiestrogen) therapy in advanced breast cancer.
    Kiang DT; Kennedy BJ
    Ann Intern Med; 1977 Dec; 87(6):687-90. PubMed ID: 931204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study Nolvadex: tamoxifen citrate in the treatment of advanced prostatic adenocarcinoma.
    Spremulli E; DeSimone P; Durant J
    Am J Clin Oncol; 1982 Apr; 5(2):149-53. PubMed ID: 7091040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy.
    Hoff PM; Valero V; Buzdar AU; Singletary SE; Theriault RL; Booser D; Asmar L; Frye D; McNeese MD; Hortobagyi GN
    Cancer; 2000 May; 88(9):2054-60. PubMed ID: 10813717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
    Ravdin PM; Green S; Dorr TM; McGuire WL; Fabian C; Pugh RP; Carter RD; Rivkin SE; Borst JR; Belt RJ
    J Clin Oncol; 1992 Aug; 10(8):1284-91. PubMed ID: 1634918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer.
    Matelski H; Greene R; Huberman M; Lokich J; Zipoli T
    Am J Clin Oncol; 1985 Apr; 8(2):128-33. PubMed ID: 3914839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: an analysis of patients entered on four prospective clinical trials.
    Dhodapkar MV; Ingle JN; Cha SS; Mailliard JA; Wieand HS
    Cancer; 1996 Feb; 77(4):683-90. PubMed ID: 8616760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experiences with tamoxifen for estrogen receptor blocking therapy in metastatic breast cancer.
    Henningsen B
    Prog Clin Biol Res; 1977; 12():479-82. PubMed ID: 918118
    [No Abstract]   [Full Text] [Related]  

  • 13. Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer: a Southeastern Cancer Study Group trial.
    Gockerman JP; Spremulli EN; Raney M; Logan T
    Cancer Treat Rep; 1986 Oct; 70(10):1199-203. PubMed ID: 3530447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer.
    Fowble B; Fein DA; Hanlon AL; Eisenberg BL; Hoffman JP; Sigurdson ER; Daly MB; Goldstein LJ
    Int J Radiat Oncol Biol Phys; 1996 Jul; 35(4):669-77. PubMed ID: 8690632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oestrogen receptors and the response of metastatic breast cancer to aminoglutethimide or tamoxifen.
    Holdaway IM
    Aust N Z J Surg; 1981 Aug; 51(4):345-7. PubMed ID: 6944051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
    Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
    Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trials with toremifene in advanced breast cancer: a review.
    Valavaara R
    Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S31-5. PubMed ID: 2149283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association.
    Muss HB; Wells HB; Paschold EH; Black WR; Cooper MR; Capizzi RL; Christian R; Cruz JM; Jackson DV; Powell BL
    J Clin Oncol; 1988 Jul; 6(7):1098-106. PubMed ID: 3292710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiestrogens--tamoxifen, SERMs and beyond.
    Dhingra K
    Invest New Drugs; 1999; 17(3):285-311. PubMed ID: 10665480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
    Johnston SR
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.